Low expression of CYB5R2 showed a significant correlation with a better prognosis in CD5+ DLBCL in the univariate but not in the multivariate survival analysis, indicating that the favorable prognosis of CYB5R2-Low cases was probably attributed to other factors, such as the COO. This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.